GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced that 2026 will be a pivotal inflection year driven by multiple late-stage clinical, regulatory, and manufacturing milestones across its diversified portfolio, following engagements during the J.P. Morgan Healthcare Conference Week in San Francisco.
David Dodd, Chairman & CEO of GeoVax, stated that the company enters 2026 with increasing clarity on execution, prioritization, and value creation. He highlighted GEO-MVA as representing an expedited path to potential commercialization, alongside multiple clinical data readouts for GEO-CM04S1, their multi-antigen COVID-19 vaccine, and the anticipated initiation of the Phase 2 Gedeptin trial. Dodd noted that feedback from investors, potential strategic partners, and global health stakeholders reinforces confidence that 2026 has the potential to be a breakout year.
GEO-MVA, the company's most advanced program targeting Mpox and smallpox, is positioned for a near-term commercialization opportunity. The global vaccine market remains constrained by reliance on a single foreign manufacturer, creating a structural supply imbalance. Following supportive Scientific Advice from the European Medicines Agency (EMA), GeoVax has regulatory alignment on a single, pivotal Phase 3 immunobridging study versus the approved MVA vaccine, de-risking the regulatory path. Key 2026 milestones include initiation of the pivotal Phase 3 trial in the second half of 2026, continued engagement with global health authorities, and advancement toward a U.S.-sourced vaccine supply model for civilian and biodefense needs. Clinical material is already manufactured and fill-finished, positioning the program for Phase 3 execution.
In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy, following encouraging safety and tumor-response signals. 2026 inflection points include publication of results from the completed trial, initiation of a Phase 2 study evaluating Gedeptin in combination with an immune checkpoint inhibitor for head and neck cancer by year-end, and updates on preclinical evaluations for potential expansion into other solid tumors. The company pursues a partnership-oriented development strategy for Gedeptin.
For GEO-CM04S1, a next-generation COVID-19 vaccine designed for immunocompromised and high-risk populations, 2026 will see clinical data readouts from ongoing Phase 2 trials, continued evaluation as a primary and booster vaccine in immunocompromised patients, and additional translational insights for regulatory and partnering discussions.
The AGE1 continuous avian cell-line manufacturing process is integrated into the GEO-MVA program, enabling scalable, U.S.-based production. Manufacturing progress in 2026 includes continued optimization for commercial-scale production and advancement as a solution for pandemic preparedness and supply-chain resilience.
Dodd concluded that GeoVax is moving beyond platform validation, executing against defined milestones with GEO-MVA leading the portfolio and multiple programs advancing toward value-inflection events. He emphasized that years of platform development, regulatory engagement, and manufacturing investment are translating into tangible outcomes, positioning the company for a pivotal year of execution and value creation.
For more information, visit www.geovax.com.
